Photo from Erman Akkus/X
Aug 12, 2024, 21:46
GI cancers – rapid oral abstracs in ASCOBT 24 summarized by Erman Akkus
Erman Akkus, Medical Oncology Fellow at Ankara University Faculty of Medicine, shared on X:
“GI cancers- rapid oral abstracts in ASCOBT (Breakthrough) 24.
- 221- The impact of HRD mutation on survival in patients with KRAS-mutated advanced pancreatic cancer.
HRD+ve pts had better time-to-treatment failure when treated with mFOLFIRINOX, but not with gemcitabine-nab-paclitaxel.
- 196- Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial).
Bite-on-bite biopsies and EUS-FNA for lymph nodes are accurate, ctDNA may help.
- 50- Outcomes in Child-Pugh (CP) B liver function treated with atezolizumab plus bevacizumab (A+B) for hepatocellular carcinoma (HCC).
No additional safety risks, may still benefit.
- 34- Phase Ib trial of durvalumab plus tremelimumab in combination with particle therapy in advanced HCC with macrovascular invasion: Departure.
The combination is safe.”
Source: Erman Akkus/X
Other posts featuring Erman Akkus on OncoDaily.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 13:46
Dec 21, 2024, 13:40
Dec 21, 2024, 13:33
Dec 21, 2024, 13:20
Dec 21, 2024, 13:12